Bharat Immunological & Biological Corporation Ltd, Syncom Formulations (India) Ltd, Earum Pharmaceuticals Ltd and Manaksia Aluminium Company Ltd are among the other gainers in the BSE’s ‘B’ group today, 23 December 2022.

Gyscoal Alloys Ltd leads gainers in ‘B’ group

Earum Pharmaceuticals standalone net profit declines 99.26% in the September 2022 quarter

Rajdarshan Industries Ltd, Parsvnath Developers Ltd, Usha Martin Education & Solutions Ltd and Kanani Industries Ltd are among the other losers in the BSE’s ‘B’ group today, 21 July 2022.

Earum Pharmaceuticals Ltd leads losers in ‘B’ group

Ceinsys Tech Ltd, Earum Pharmaceuticals Ltd, Patel Integrated Logistics Ltd Partly Paidup and Maximus International Ltd are among the other losers in the BSE’s ‘B’ group today, 29 June 2022.

Salasar Techno Engineering Ltd leads losers in ‘B’ group

Vishal Bearings Ltd, Loyal Equipments Ltd, Star Health & Allied Insurance Company Ltd and Earum Pharmaceuticals Ltd are among the other losers in the BSE’s ‘B’ group today, 24 June 2022.

Wardwizard Innovations & Mobility Ltd PartlyPaidup leads losers in ‘B’ group

Earum Pharmaceuticals Ltd, Compuage Infocom Ltd, Jain Irrigation Systems Ltd-DVR and Star Health & Allied Insurance Company Ltd are among the other losers in the BSE’s ‘B’ group today, 23 June 2022.

Sambhaav Media Ltd, Jindal Worldwide Ltd, Lloyds Metals & Energy Ltd and Nagarjuna Fertilizers & Chemicals Ltd are among the other losers in the BSE’s ‘B’ group today, 21 April 2022.

Earum Pharmaceuticals reports standalone net loss of Rs 0.72 crore in the March 2022 quarter

Earum Pharmaceuticals reports standalone net profit of Rs 0.95 crore in the December 2021 quarter

Manaksia Aluminium Company Ltd, Om Infra Ltd, Earum Pharmaceuticals Ltd and 3i Infotech Ltd are among the other losers in the BSE’s ‘B’ group today, 23 December 2021.

Cyber Media (India) Ltd leads losers in ‘B’ group

Earum Pharmaceuticals was locked in an upper-circuit of 5% at Rs 70.35 after the company fixed Saturday, 18 December 2021 as the record date for determining eligibility of members for the purpose of sub-division of the equity shares of the company.

Earum Pharmaceuticals hits the roof ahead of record date for stock split

Hasn't faired well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Financials growth has been moderate for a few years

Growth

Showing good signs of profitability & efficiency

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Earum Pharmaceuticals is engaged in the pharmaceutical business involving marketing, trading and distribution of wide range of pharmaceutical formulation products such as anti-biotic drugs, anti-malarial drugs, anti-allergic & anti cold drugs etc